Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03530514
Recruitment Status : Recruiting
First Posted : May 21, 2018
Last Update Posted : November 15, 2019
Sponsor:
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

Brief Summary:

The primary objective of the study is to evaluate the safety and tolerability of REGN4461 in healthy participants. The secondary objectives of the study are to:

  • Characterize the Pharmacokinetic (PK) profile of single and repeated doses of REGN4461 and evaluate the effects of baseline covariates on PK profile
  • Estimate the effects of repeated doses of REGN4461 on body weight over 12 weeks in overweight and obese participants
  • Assess the effects of repeated doses of REGN4461 on ad lib energy intake in overweight and obese participants
  • Evaluate the effects of single and repeated doses of REGN4461 on soluble forms of lipid-regulating proteins levels over time
  • Assess the immunogenicity of single and repeated doses of REGN4461

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: REGN4461 Drug: Placebo Phase 1

Detailed Description:
This is a 2-part study of the safety, tolerability, PK and pharmacodynamic (PD) of single and repeated doses of REGN4461 in healthy participants. In Part A, healthy lean or overweight participants will be enrolled to evaluate the safety, tolerability, PK, and PD of single ascending intravenous (IV) and subcutaneous (SC) doses. Interim PK and safety information from Part A will be used to select the dose level, frequency, and mode of administration (IV or SC) for repeat dosing in Part B. In Part B, overweight/obese participants with body mass index (BMI) 25-40 kg/m2 will be enrolled to evaluate the safety, tolerability, PK, and PD of repeated doses of REGN4461 in 4 distinct cohorts defined by baseline leptin levels.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 169 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, 2-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, And Pharmacodynamics of Single and Multiple Doses of REGN4461 in Healthy Subjects
Actual Study Start Date : April 24, 2018
Estimated Primary Completion Date : January 27, 2020
Estimated Study Completion Date : January 27, 2020

Arm Intervention/treatment
Experimental: Part A: Single dose cohort 1
Cohort 1 will receive a single IV dose of REGN4461 or matching placebo
Drug: REGN4461
REGN4461

Drug: Placebo
Placebo-matching REGN4461

Experimental: Part A: Single dose cohort 2
Cohort 2 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
Drug: REGN4461
REGN4461

Drug: Placebo
Placebo-matching REGN4461

Experimental: Part A: Single dose cohort 3
Cohort 3 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
Drug: REGN4461
REGN4461

Drug: Placebo
Placebo-matching REGN4461

Experimental: Part A: Single dose cohort 4
Cohort 4 will receive a sequential ascending single SC dose of REGN4461 or matching placebo
Drug: REGN4461
REGN4461

Drug: Placebo
Placebo-matching REGN4461

Experimental: Part A: Single dose cohort 5
Cohort 5 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
Drug: REGN4461
REGN4461

Drug: Placebo
Placebo-matching REGN4461

Experimental: Part A: Single dose cohort 6
Cohort 6 will receive a sequential ascending single SC dose of REGN4461 or matching placebo
Drug: REGN4461
REGN4461

Drug: Placebo
Placebo-matching REGN4461

Experimental: Part A: Single dose cohort 7
Cohort 7 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
Drug: REGN4461
REGN4461

Drug: Placebo
Placebo-matching REGN4461

Experimental: Part A: Single dose cohort 8
Cohort 8 will receive a single IV dose of REGN4461 or matching placebo
Drug: REGN4461
REGN4461

Drug: Placebo
Placebo-matching REGN4461

Experimental: Part A: Single dose cohort 9
Cohort 9 will receive a single IV dose of REGN4461 or matching placebo
Drug: REGN4461
REGN4461

Drug: Placebo
Placebo-matching REGN4461

Experimental: Part B: Repeated dose cohort 10
Cohort 10 will receive repeated IV or SC doses of REGN4461 or matching placebo
Drug: REGN4461
REGN4461

Drug: Placebo
Placebo-matching REGN4461




Primary Outcome Measures :
  1. Number of treatment-emergent adverse events (TEAEs) [ Time Frame: Up to week 27 ]

Secondary Outcome Measures :
  1. Concentrations of REGN4461 in serum over time [ Time Frame: Up to week 27 ]
  2. Percent change from baseline to week 12 in body weight in overweight or obese participants [ Time Frame: Baseline to week 12 ]
  3. Absolute change from baseline to week 12 in body weight in overweight or obese participants [ Time Frame: Baseline to week 12 ]
  4. Change from baseline in caloric intake in response to standardized meals in overweight or obese participants [ Time Frame: Baseline to week 12 ]
  5. Change in lipid-regulating protein levels over time after single doses of REGN4461 [ Time Frame: Up to week 16 ]
  6. Change in lipid-regulating protein levels over time after repeated doses of REGN4461 [ Time Frame: Up to week 27 ]
  7. Incidence of anti-drug antibodies to REGN4461 over time after single doses of REGN4461 [ Time Frame: Up to week 16 ]
  8. Incidence of anti-drug antibodies to REGN4461 over time after repeated doses of REGN4461 [ Time Frame: Up to week 27 ]
  9. Pharmacokinetic (PK) parameter: Area under curve (AUC) computed from time zero to the time of the last positive concentration (AUClast) [ Time Frame: Up to week 27 ]
  10. PK parameter: AUC computed across a dosing interval with length τ (AUCo-τ) [ Time Frame: Upt to week 27 ]
  11. PK parameter: peak concentration (Cmax) [ Time Frame: Up to week 27 ]
  12. PK parameter: time to Cmax (tmax) [ Time Frame: Up to week 27 ]
  13. PK parameter: clearance (CL) [ Time Frame: Up to week 27 ]
  14. PK parameter: trough concentration (Ctrough) [ Time Frame: Up to week 27 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Key Inclusion Criteria

Part A:

  1. Males and females 18 to 50 years of age, inclusive
  2. Body mass index (BMI) from 18.5 to <30.0 kg/m^2
  3. Participant is judged by the investigator to be in good health and free from major comorbidities based on medical history, physical examination, laboratory safety tests performed at screening and/or prior to administration of initial dose of study drug

Part B:

  1. Males and females 18 to 65 years of age, inclusive
  2. Have a body mass index (BMI) from 25.0 to 40.0 kg/m^2
  3. Participant is judged by the investigator to be free from major comorbidities based upon medical history, physical examination, laboratory safety tests performed at screening and/or prior to administration of initial dose of study drug. Participants can have a history of mild hyperlipidemia and/or mild hypertension but should be on stable doses of lipid lowering or blood pressure lowering medicines for at least 2 months prior to screening

Key Exclusion Criteria

Part A:

  1. History of type 1 or 2 diabetes or prediabetes or with fasting blood glucose (FBG) at screening ≥ 100mg/dL or with HbA1c at screening of ≥ 5.7%.
  2. Fasting LDL-C ≥ 130mg/dL, TG ≥ 250 mg/dL

Part B:

  1. History of type 1 or 2 diabetes or with FBG at screening ≥ 126 mg/dL or with HbA1c at screening of ≥ 6.5%. A diagnosis of "pre-diabetes" is allowed.
  2. Fasting LDL-C ≥ 160 or TG ≥ 500 mg/dL

Key Exclusion Criteria (Parts A and B):

  1. Hospitalization (ie, >24 hours) for any reason within 60 days of the screening visit
  2. History of hypothalamic amenorrhea or lipodystrophy.
  3. Change in body weight of more than 5% over the past 3 months prior to screening.
  4. Previous history of bariatric procedures for obesity (eg, sleeve gastrectomy, gastric bypass, banding, etc).
  5. Procedures for weight reduction (eg, liposuction) or body contouring in the past 6 months.
  6. Treatment with medications for (over-the-counter [OTC] or prescribed) weight loss (eg, lorcaserin, phentermine/topiramate, naltrexone HCl/bupropion HCl, liraglutide) in the past 3 months.
  7. History of major psychiatric disorders, eating disorders (eg, bulimia, anorexia).
  8. Current cigarette smoker or former smoker (cigarettes or e-cigarettes) who stopped smoking within 3 months prior to screening.
  9. History of recreational drug (including marijuana) or alcohol abuse (>2 drinks per day) within a year prior to the screening visit.
  10. History of hepatitis B infection or a positive hepatitis B surface antigen (HbsAg+) at screening
  11. History of HIV infection or HIV seropositive at the screening visit.
  12. History of hepatitis C infection or positive hepatitis C antibody test result at screening.
  13. Pregnant or breastfeeding women.

Note: Other inclusion/ exclusion criteria apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03530514


Contacts
Layout table for location contacts
Contact: Clinical Trial Administrator 844-734-6643 clinicaltrials@regeneron.com

Locations
Layout table for location information
Belgium
Regeneron Investigational Site Recruiting
Antwerp, Belgium
Sponsors and Collaborators
Regeneron Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Clinical Trial Management Regeneron Pharmaceuticals

Layout table for additonal information
Responsible Party: Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03530514     History of Changes
Other Study ID Numbers: R4461-HV-1794
2018-000327-14 ( EudraCT Number )
First Posted: May 21, 2018    Key Record Dates
Last Update Posted: November 15, 2019
Last Verified: November 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No